ERBB2 and breast cancer: Until 2018, before the introduction of trastuzumab biosimilars to the Italian market, trastuzumab-based regimens were regularly provided for neoadjuvant, adjuvant, and metastatic treatment of patients with HER2-positive BC, both as intravenous (IV) and subcutaneous (SC) formulation.